September 29, 2023 News by Lindsey Shapiro, PhD Stem cell therapy found safe, effective in RRMS study Nearly three-quarters of people with relapsing-remitting multiple sclerosis (RRMS) showed no signs of disease activity five years after receiving a stem cell transplant, according to a recent Swedish study. Moreover, about half of patients with at least minimal disability saw improvements after the transplant and about one-third remained stable.
May 22, 2023 News by Marisa Wexler, MS Stem cell therapy may be better than some DMTs for highly active RRMS Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability for people with highly active relapsing-remitting multiple sclerosis (RRMS), a new analysis suggests. In contrast, findings suggest that the efficacy of stem cell therapy is not significantly different…
April 28, 2023 News by Marisa Wexler, MS AAN 2023: Low rates of disease activity after stem cell transplant There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent an autologous hematopoietic stem cell transplant (aHSCT) at a center in Mexico. And by the most recent follow-up — a median of about seven years after the procedure —…
July 28, 2021 News by Forest Ray PhD FDA Greenlights Stem Cells Trial Aiming to Improve Quality of Life The U.S. Food and Drug Administration (FDA) has given the green light to a Phase 2 clinical trial that will assess the efficacy of using adult mesenchymal stem cells (MSCs) to treat the symptoms of mild to moderate multiple sclerosis (MS). The non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF),…
February 20, 2020 News by Joana Carvalho, PhD Bone Marrow Transplant Can Replace Overactive Immune Cells, Preventing Inflammation in MS, Study Says A bone marrow transplant can remove the majority of overactive immune T cells from the central nervous system (CNS) in patients with active relapsing-remitting multiple sclerosis (RRMS), allowing the body to replace them with healthy ones, a study has found. This opens up new treatment avenues to…
January 14, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Stimulator for Spasticity, Tysabri Dosing Trial, Mobility Devices Contest, Stem Cell Phase 2 Trial WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this…
February 3, 2017 News by Patricia Silva, PhD Clinical Trial Supports Stem Cell Transplants to Treat RMS Patients with High Disease Activity A newly concluded clinical trial gives scientific evidence of the benefits that a stem cell transplant holds for multiple sclerosis (MS) patients who fail to respond to medications — with researchers calling the procedure a reasonable option for those with high disease activity. Five years after the treatment — high-dose immunosuppressive therapy followed by autologous hematopoietic cell transplant — further disease…
